News AZ immunotherapy gets FDA boost in early lung cancer Imfinzi given Breakthrough Therapy designation from the FDA.
News LifeArc spends Keytruda cash on R&D ignored by pharma Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
News Major UK market breakthrough for Keytruda in lung cancer But funding will last only two years on CDF.
News Merck tries again in Alzheimer's with Teijin's tau antibody Target is implicated in a number of nervous system diseases.
News Keytruda wins another first with approval based on biomarker... For the first time, FDA approves drug on the basis of biomarkers, rather than location.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.